

1648 \$  
ATTORNEY DOCKET NO. UCSF.002.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Vishwanath R. Lingappa, et al.** ) Examiner: Winkler, Ulrike  
Serial No.: **10/040,206** ) Art Unit: 1648  
Filed: **January 2, 2002** )  
For: **HIV Capsid Assembly-Associated** ) **TRANSMITTAL LETTER**  
**Compositions and Methods** )

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

Transmitted herewith are the following documents in the above-identified application.

- ☐ Small entity status of this Application under 37 CFR 1.9 and 1.27 has been established by a Verified Declaration previously submitted.
- ☐ A Verified Declaration of Small Entity Status Under 37 CFR 1.9 and 1.27 is enclosed.
- ☒ Response to Restriction Requirement.
- ☒ Marked Copy of Claims
- ☒ Clean Copy of Claims
- ☒ Replacement Page 58
- ☒ Petition for Extension of Time (1 month).

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231:

April 4, 2003  
(Date)  
  
(Signature)  
Carrie Bucher  
(Printed Name)

RECEIVED  
APR 15 2003  
TECH CENTER 1600/2900

**PATENT****ATTORNEY DOCKET NO. UCSF.002.01US**

Also enclosed:

- ☒ Return postcard (postage prepaid).  
☐ Terminal Disclaimer under 37 CFR 1.20(d).

The fees have been calculated as shown below:

<u>Claims</u>	<u>Remaining after Amend</u>	<u>Highest No. Prev. Paid</u>	<u>Pres. Extra</u>	<u>Small Entity</u>		<u>Large Entity</u>	
				<u>Rate</u>	<u>Fee</u>	<u>Rate</u>	<u>Fee</u>
Total:	6	50	0	x \$9	= \$0	x \$18	= \$0
Indep:	2	20	0	x \$42	= \$0	x \$84	= \$0

If Multiple dependent Claims are used for the first time in this application, add \$140 (small entity) \$280 (large entity).

**Total Additional Claims Fee: \$0.00**

<u>Extension of Time Fee</u>	<u>Small Entity</u>	<u>Large Entity</u>
<input checked="" type="checkbox"/> One Month	\$55	\$ 110
<input type="checkbox"/> Two Months	\$205	\$ 410
<input type="checkbox"/> Three Months	\$465	\$ 930
<input type="checkbox"/> Four Months	\$725	\$1450
<input type="checkbox"/> Five Months	\$985	\$1970

**Extension of Time Fee \$55.00**

Other fees (list individually):

**Total Other Fees: \$0.00****TOTAL FEES: \$55.00**

- ☒ A check including the amount of the above-indicated TOTAL FEES is attached.  
☐ Please charge Deposit Account No. 18-0020 in the amount of \$.  
☐ No fee is required.


**PATENT**

**ATTORNEY DOCKET NO. UCSF.002.01US**

- ☒ Conditional Petition for Extension of Time: An extension of time is requested in the present and/or the above-referenced parent application to provide for timely filing if an extension of time is still required after all papers filed with this transmittal have been considered.
- ☒ The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 18-0020.
- ☒ Any filing fees under 37 CFR 1.16 including fees for the presentation of extra claims.
- ☒ Any parent application processing fees under 37 CFR 1.17.
- ☒ A **duplicate** copy of this sheet is attached for accounting purposes.

Respectfully submitted,

Date: April 4, 2003



Barbara Rae-Venter, Ph.D.  
Reg. No. 32,750

Rae-Venter Law Group, P.C.  
PO Box 1898  
Monterey, CA 93942-1898  
Phone: (831) 648-3090  
Facsimile: (831) 242-0137

BRV/mnb  
Enclosures



ATTORNEY DOCKET NO. UCSF.002.01US

#15  
Elec./  
Amend.B  
4.16.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: <b>Vishwanath R. Lingappa, et al.</b>	) Examiner: Winkler, Uirike
	)
Serial No.: <b>10/040,206</b>	) Art Unit: 1648
	)
Filed: <b>January 2, 2002</b>	)
	)
For: <b>HIV Capsid Assembly-Associated</b>	) <b><u>RESPONSE TO RESTRICTION</u></b>
<b>Compositions and Methods</b>	) <b><u>REQUIREMENT</u></b>
	)

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

RECEIVED  
APR 15 2003  
TECH CENTER 1600/2900

This is in response to the Restriction Requirement mailed February 4, 2003 and is submitted on or before April 4, 2003, the time period for response having been extended by the attached Petition for Extension of Time and the Requisite Fee.

The Examiner is respectfully requested to make the following amendments shown on the attached Marked Up Version of the Claims. A Clean Copy of the Claims as amended is also attached together with replacement page 58.

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231:

\_\_\_\_\_  
(Date) April 4, 2003

\_\_\_\_\_  
(Signature) Carrie Bucher

\_\_\_\_\_  
(Printed Name) Carrie Bucher

PATENT

ATTORNEY DOCKET NO. UCSF.002.01US

The Examiner has required restriction among the following Groups under U.S.C. 121:

- I. Claims 1-6, drawn to a method of isolating an HIV capsid intermediate, classified in class 530, subclass 412.
- II. Claims 7-9, drawn to a method of identifying a chaperone protein for HIV capsid assembly, classified in class 436, subclass 501.
- III. Claims 10 and 11, drawn to a method of identifying a conformer of a host cell protein involved in HIV capsid assembly, classified in class 430, subclass 344.
- IV. Claims 12-14, drawn to a method of producing a monoclonal antibody that recognizes a conformer involved in HIV capsid assembly, classified in class 530, subclass 388.1
- V. Claims 15 and 19, drawn to a method of identifying the structure of the interaction between the chaperone protein and the HIV capsid intermediate, classified in class 435, subclass 7.1
- VI. Claims 16-18, 20 and 21, drawn to a method of identifying compounds that interfere with capsid assembly, classified in class 435, subclass 4.
- VII. Claims 22-23, drawn to a method of identifying conformers of the HIV assembly chaperones in an HIV infected individual, classified in class 424, subclass 9.2.
- VIII. Claims 24-28 and 40, drawn to an HIV capsid intermediate, classified in class 424, subclass 208.1.
- IX. Claims 29-34, drawn to a cell free system for producing an HIV capsid intermediate, classified in class 800, subclass 320.1.
- X. Claims 35-39 and 50, drawn to a method of producing an HIV capsid intermediate using a cell free system, classified in class 436, subclass 534.
- XI. Claims 41-42 and 46-47, drawn to a method of selecting a compound capable of altering HIV assembly by using a cell free transition mixture, classified in class 424, subclass 9.2.
- XII. Claims 43-45, drawn to a host cell protein, classified in class 530, subclass 350.
- XIII. Claims 48-49, drawn to a method of selecting a compound that is capable of altering HIV assembly in a cell, classified in class 424, subclass 9.2

Applicants hereby elect Group IV, Claims 12-14, without traverse.

Respectfully submitted,

Date: April 11, 2003

Barbara Rae-Venter

Barbara Rae-Venter, Ph.D.  
Reg. No. 32,750

Rae-Venter Law Group, P.C.  
PO Box 1898  
Monterey, CA 93942-1898  
Phone: (831) 648-3090  
Facsimile: (831) 242-0137

BRV/mnb